Xcout IntelBiomea Fusion, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Biomea Fusion, Inc. among biotech companies — ranked by similarity to what Biomea Fusion, Inc. actually does, not by market-cap band.
Subscribe to see Biomea Fusion, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Biomea Fusion, Inc.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Biomea Fusion, Inc. at a glance
Biomea Fusion, Inc. is a biotech company headquartered in San Carlos, United States. It is publicly listed (BMEA) with a market capitalisation of $90.4M. Xcout tracks 21 named people at Biomea Fusion, Inc., including Michael J. Hitchcock (Interim Chief Executive Officer & Director).
Biomea Fusion, Inc. leadership
- Michael J. HitchcockInterim Chief Executive Officer & Director
- Michael Mick Hitchcock, Ph.D.Interim CEO
- Heow TanChief Technology & Quality Officer
- Stephan MorrisChief Development Officer
- Stephan Steve W. Morris, M.D.Chief Development Officer
- Ramses ErdtmannCo-Founder, President, Chief Operating Officer & Director
15 more named people on record for Biomea Fusion, Inc., with roles, board committees and tenure — see the full roster →
Biomea Fusion, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $56M | 5 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Biomea Fusion, Inc. competitors
Ranked by semantic similarity — how close each company is to Biomea Fusion, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Hinge Bio, Inc. is a privately held biotechnology company headquartered in Redwood City, California, leveraging its GEM-DIMER platform to design and develop therapeutics for cancer as well as autoimmune and inflammatory diseases.
Similar biotech company
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Similar biotech company
Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19. Another asset, NKTR-358, a cytokine Treg stimulant, is progressing through Phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis, alongside Phase 1B studies for atopic dermatitis and psoriasis. Furthermore, NKTR-255, an IL-15 receptor agonist, is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. The company's portfolio also includes NKTR-262, a toll-like receptor agonist in Phase 1/2 trials for solid tumors, among other developmental drug candidates. Nektar has established significant collaborative agreements with a wide array of pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Similar biotech company
Frontier Medicines, Corp. is a precision medicine company focusing on drug development with offices in locations including South San Francisco, California, and Boston.
Similar biotech company
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Similar biotech company
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.
Biotechnology
76Bio, Inc. is a biotechnology company founded in 2020 and based in Boston, United States. The company develops therapeutics for patients with life-threatening diseases by pioneering targeted protein degraders.
Biotechnology
Link Cell Therapies Inc. is a platform biotechnology company maintaining its headquarters in South San Francisco, California. The company develops novel agents targeting hematologic and related diseases.
Biotechnology
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
Biotechnology
Alixia, Inc. is a biotechnology company that develops therapeutics targeting tumor ecosystems to address cancer drug resistance and complex, chronic diseases. The company utilizes a research platform integrating biology, biophysics, computational chemistry, and clinical input to discover lead compounds that disrupt metabolic and inflammatory triggers within the tumor microenvironment.
Similar biotech company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Similar biotech company
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Biomea Fusion, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Biomea Fusion, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →